✨
AI Summary
- Midyear review of biopharma dealmaking in 2024.
- Analysis of H1 deal data and future expectations.
- Industry mood post-BIO conference and insights from meetings.
Guests on This Episode
JH
Joseph Haas
4 podcast appearances
KG
Kevin Grogan
4 podcast appearances
MJ
Mandy Jackson
2 podcast appearances